Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
G7 nations commit to phasing out coal by 2035 but give Japan some flexibility
MILAN (AP) — Energy and environment ministers of the Group of Seven leading industrialized nations c2024-05-01EDITORIAL: Plan needed so no quake victims will ever be left behind again
Thirteen years have passed since the Great East Japan Earthquake devastated the northeastern region2024-05-01Weather: Easter weekend chill calls for extra layers
The South Island will see the sun, the North Island will have some unsettled weather. Photo: Unsplas2024-05-01Using a walker boot for too long may mean you can't ever walk properly without it again
For any self-respecting fashion icon, the right choice of footwear is clearly important. But after b2024-05-01US intends further strikes on Iran
Merchants wait for customers at the old market in Sanaa, Yemen, on 4 February, where residents of th2024-05-01
atest comment